Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 20, 2019Journal of Clinical Oncology

West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

UNUlrike Anneliese NitzDeutsches Archäologisches Institut, ZentraleOGOleg GluzBethesda HospitalMCMichael ClemensKlinikum Saarbrücken

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Nitz et al. (2019) studied this question.

synapsesocial.com/papers/693dfe8a35a649d042a9a130https://doi.org/10.1200/jco.18.00028
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Anthracyclines in Early Breast Cancer: The ABC Trials—USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology)2017 · 276 citations
  2. 2Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer2018 · 2,071 citations